woman
histori
hypertens
hyperlipidemia
remot
breast
gastric
cancer
present
hospit
subject
fever
diffus
myalgia
cough
dyspnea
exert
deni
recent
travel
contact
recent
travel
sick
individu
initi
examin
patient
temperatur
heart
rate
beatsmin
newonset
atrial
fibril
hypoxia
requir
l
oxygen
via
nasal
cannula
maintain
oxygen
satur
initi
blood
pressur
normal
laboratori
evalu
notabl
normal
white
blood
cell
count
cellsl
normal
complet
metabol
panel
mildli
elev
lactat
mmoll
chest
radiographi
demonstr
moder
bilater
pulmonari
infiltr
respiratori
panel
polymeras
chain
reaction
pcr
neg
pend
nasal
pcr
place
isol
treat
empir
communityacquir
pneumonia
ceftriaxon
azithromycin
start
continu
heparin
infus
due
new
atrial
fibril
four
hour
admiss
patient
develop
rapidli
progress
hypox
respiratori
failur
requir
temporari
highflow
nasal
cannula
hfnc
stabil
transfer
intens
care
unit
icu
repeat
chest
radiographi
demonstr
sever
bilater
patchi
opac
intub
rapid
sequenc
techniqu
without
use
bagvalvemask
ventil
limit
aerosol
instead
maintain
hfnc
apneic
ventil
intub
transmiss
rate
hfnc
shown
less
bagvalvemask
initi
ard
clinic
network
ardsnet
protocol
lung
protect
strategi
persist
hypoxia
ratio
p
f
ratio
despit
neuromuscular
blockad
ventil
prone
posit
led
signific
improv
p
f
ratio
nasal
pcr
posit
hour
admiss
inflammatori
marker
elev
interleukin
level
pgml
ferritin
mgdl
ddimer
consist
poor
prognosi
fortyeight
hour
admiss
develop
renal
hepat
failur
sever
hypotens
requir
norepinephrin
vasopressin
bedsid
echocardiographi
demonstr
newli
reduc
eject
fraction
apic
balloon
consist
stressinduc
cardiomyopathi
set
multiorgan
failur
candid
remdesivir
avail
time
diagnosi
given
progress
escal
vasopressor
requir
concern
catecholamineresist
shock
angiotensin
ii
initi
therapi
led
rapid
improv
blood
pressur
norepinephrin
vasopressin
wean
within
hour
also
start
inhal
nitric
oxid
due
possibl
antivir
effect
note
start
hydroxychloroquin
azithromycin
hospit
day
follow
recent
publish
evid
exhibit
improv
start
medic
despit
remain
hemodynam
stabl
procalcitonin
trend
next
sever
day
prompt
empir
treatment
vancomycin
meropenem
isavuconazol
ad
due
report
invas
aspergillosi
case
china
procalcitonin
lactat
dehydrogenas
peak
broaden
antimicrobi
downtrend
daili
prone
ventil
stop
p
f
ratio
maintain
supin
posit
angiotensin
ii
discontinu
day
initi
without
need
vasopressor
patient
remain
intub
fail
trial
extub
hospit
day
due
respiratori
weak
otherwis
clinic
stabl
normal
renal
hepat
function
repeat
chest
xray
reintub
demonstr
resolut
ard
pattern
benefit
risk
tracheostomi
set
pandem
current
discuss
famili
surgic
servic
sinc
outbreak
decemb
extens
research
possibl
treatment
howev
proven
effect
therapi
date
death
rate
among
elderli
comorbid
describ
case
elderli
person
multipl
comorbid
multiorgan
system
failur
surviv
proper
manag
ard
sever
experiment
therapi
determin
individu
impact
therapi
believ
initi
angiotensin
ii
play
signific
role
hemodynam
stabil
warrant
investig
patient
use
angiotensin
ii
multipl
possibl
benefit
patient
first
welldescrib
cytokin
storm
phase
lead
profound
vasodilatori
shock
angiotensin
ii
well
establish
effect
second
acut
renal
failur
uncommon
patient
requir
renal
replac
post
hoc
analysi
angiotensin
treatment
vasodilatori
shock
atho
iii
trial
show
signific
benefit
use
angiotensin
ii
patient
vasodilatori
shock
renal
failur
specif
show
decreas
number
day
renal
replac
therapi
compar
decreas
need
renal
replac
therapi
could
signific
benefit
resourcelimit
environ
pandem
third
recent
articl
argu
physiolog
benefit
use
exogen
angiotensin
ii
improv
possibl
angiotensin
ii
defici
possibl
downregul
howev
physiolog
argument
remain
controversi
chines
studi
februari
show
correl
elev
level
endogen
angiotensin
ii
lung
injuri
patient
rais
concern
use
exogen
angiotensin
ii
patient
howev
elev
level
angiotensin
ii
also
note
patient
vasodilatori
shock
athosiii
trial
angiotensin
ii
elev
actual
found
repres
rel
defici
compar
markedli
elev
angiotensin
level
fact
patient
show
signific
hemodynam
improv
angiotensin
ii
could
point
toward
therapeut
use
angiotensin
ii
patient
patient
vasodilatori
shock
secondari
signific
consider
use
angiotensin
ii
first
frequent
use
patient
cardiomyopathi
increas
afterload
add
addit
stress
left
ventricl
howev
angiotensin
ii
theoret
benefici
stress
cardiomyopathi
recommend
suggest
catecholaminespar
therapi
stressinduc
second
angiotensin
ii
link
increas
risk
venou
thromboembol
vte
compar
compound
higher
risk
vte
found
ard
thromboembol
identifi
case
patient
alreadi
maintain
heparin
infus
due
intermitt
atrial
fibril
case
angiotensin
ii
safe
use
patient
cardiomyopathi
vasodilatori
shock
rapid
improv
hemodynam
vasopressor
requir
without
advers
effect
given
possibl
benefit
believ
research
warrant
safeti
efficaci
use
angiotensin
ii
patient
name
kevin
bobeck
md
contribut
author
help
review
literatur
gather
relev
patient
data
write
manuscript
abstract
name
arthur
w
holtzclaw
md
contribut
author
help
review
literatur
gather
relev
patient
data
write
manuscript
abstract
name
tara
e
brown
md
contribut
author
help
review
literatur
gather
relev
patient
data
write
manuscript
abstract
name
paul
clark
contribut
author
help
review
literatur
gather
relev
patient
data
write
manuscript
abstract
manuscript
handl
bobbiejean
sweitzer
md
facp
